Aortic Valve Neocuspidization using glutaraldehyde-treated autologous pericardium: A literature review
Jeremy Chan1, Ayan Basu2, Gabriela Discenza3, Jack Bartlett4, Ka Siu Fan5, Shwe Oo6
1: MB BCh BAO, PgDip (ClinEd), Bristol Medical School, University of Bristol, Bristol, United Kingdom
2: MSc, BSc, MBBS, St George’s University of London, London, United Kingdom
3: St George’s University of London, London, United Kingdom
4: MSc, BSc, Swansea University Medical School, Swansea, United Kingdom
5: BSc, St. George’s University of London, London, United Kingdom
6: MRCS, PgCert (ClinEd), Department of Cardiothoracic Surgery, Bristol Royal Infirmary, Bristol, United Kingdom
Corresponding author
Dr Jeremy Chan MB BCh BAO, PgDip (ClinEd) Bristol Medical School University of Bristol, Bristol, United Kingdom Email:jeremychan@doctors.org.uk
Keywords: Aortic Valve Neocuspidization, Ozaki technique, Literature review
Word Count:
Funding: (None)
Disclosure: Nil
Acknowledgement: Nil
Presentation: Nil
Abstract
Background: Aortic Valve Neocuspidization using glutaraldehyde-treated autologous pericardium was first performed by Ozaki et al. in 2007. This technique has become an alternative to tissue and mechanical valve as long-term anticoagulation is not required and shows promising midterm results and durability.
Method: A comprehensive search was performed on the major database using search terms “Ozaki technique” AND “Aortic Valve Neocuspidization” AND “AV Neocuspidization” AND “Autologous pericardium” AND “glutaraldehyde-treated autologous pericardium”. Articles up to 1st of August 2020 were included in this study.
Results: A total of 9 studies with a total of 1342 patients were included. The mean age was 67.36 and 54.23% were male. 66.32% and 23.92% of patients had aortic stenosis and aortic regurgitation, respectively. 66% of patients had a native tricuspid aortic valve and 31.37 % patients’ native aortic valve was bicuspid. Three studies reported their experience performing Aortic Valve Neocuspidization via mini sternotomy.
Conclusion: Aortic Valve Neocuspidization is an alternative to biological and mechanical prostheses for surgical aortic valve replacement. The short and mid-term outcome are comparable without the need for long term oral anticoagulation. Long term follow-up data is required for this novel approach to be widely adopted.